Drug Trial Radar · NCT00835770
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
Last checked: Nov 20, 2026Latest source record: Dec 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,736
Actual
Start
Feb 3, 2009
Primary completion
Nov 8, 2019
Study completion Nov 8, 2019
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Feb 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 19 years, up to 58 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
dimethyl fumarateDrug
BG00012 capsules
PlaceboDrug
Capsules taken to maintain the blind in the 240 mg BID treatment group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (AEs)Time frame: Day 1 up to Week 561
Locations
246 sites in 34 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
research Site
Mesa, Arizona
Research Site
Phoenix, Arizona
Research Site
Loma Linda, California
Research Site
Boulder, Colorado
Research Site
Fort Collins, Colorado
Research Site
North Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Maitland, Florida
Research Site
Miami, Florida
Research Site
Naples, Florida
Research Site
Sarasota, Florida
Research Site
Tampa, Florida
Research Site
Atlanta, Georgia
Research Site
Atlanta, Georgia
Research Site
Evanston, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Kansas City, Kansas
Research Site
Wichita, Kansas
Research Site
Shreveport, Louisiana
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Boston, Massachusetts
Research Site
Farmington Hills, Michigan
Research Site
Minneapolis, Minnesota
Research Site
Chesterfield, Missouri
Research Site
St Louis, Missouri
Research Site
Albany, New York
Research Site
Amherst, New York
Research Site
Buffalo, New York
Research Site
Patchogue, New York
Research Site
Charlotte, North Carolina
Research Site
Raleigh, North Carolina
Research Site
Bellevue, Ohio
Research Site
Cleveland, Ohio
Research Site
Columbus, Ohio
Research Site
Dayton, Ohio
Research Site
Medford, Oregon
Research Site
Portland, Oregon
Showing 40 of 246 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.